Pearcey R G, Stuart G C, MacLean G D, Nation J G, Arthur K, Lukka H, Jeffrey J, James K, Brundage M
Cross Cancer Institute, Edmonton, Alberta, Canada.
Gynecol Oncol. 1995 Jul;58(1):34-41. doi: 10.1006/gyno.1995.1180.
Sixty patients presenting with poor prognosis squamous cell cancer of the cervix have been studied in a phase II clinical trial. Patients were treated with radiotherapy and concurrent cisplatin chemotherapy every 10 days. Treatment was well tolerated with all patients completing radiotherapy as prescribed. There was one case of grade 4 acute bowel toxicity. Significant late morbidity was acceptable for this group of patients being restricted to two cases (3.3%) of grade 4 toxicity to the bowel. Pelvic control rates of 78% have been observed. There have been no pelvic recurrences after 26 months, although recurrences beyond the pelvis have occurred up to 4 years later. Actuarial 4-year survival is encouraging at 60%.
在一项II期临床试验中，对60例预后不良的宫颈鳞状细胞癌患者进行了研究。患者接受放疗，并每10天同步进行顺铂化疗。所有患者均按规定完成放疗，治疗耐受性良好。有1例4级急性肠道毒性反应。对于该组患者，严重晚期发病率可接受，仅限于2例（3.3%）4级肠道毒性反应。观察到盆腔控制率为78%。26个月后无盆腔复发，尽管盆腔外复发在4年后仍有发生。4年精算生存率令人鼓舞，为60%。
